201 related articles for article (PubMed ID: 38347759)
41. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.
Reynolds VW; Chinn ME; Jolly JA; Kelley TN; Peter ME; Choi L; Nwosu S; Leon BC; Zuckerman AD
J Clin Lipidol; 2019; 13(2):254-264. PubMed ID: 30745204
[TBL] [Abstract][Full Text] [Related]
42. Process and outcomes from systemization of a longitudinal advanced pharmacy practice experience (LAPPE) program.
Deyhim N; Dunne IE; Nguyen PA; Fasoranti OO; Crew CM; Liebl MG
Am J Health Syst Pharm; 2024 Mar; 81(7):e186-e192. PubMed ID: 38070199
[TBL] [Abstract][Full Text] [Related]
43. Health-system specialty pharmacist intervention types, acceptance, and associated actions for patients with multiple sclerosis.
El-Khouri AC; Giavatto C; Hickman A; Fitzpatrick C; Mourani J; Tiger K; Rees M; Lopez-Medina AI
Am J Health Syst Pharm; 2024 May; 81(Supplement_2):S29-S39. PubMed ID: 38298009
[TBL] [Abstract][Full Text] [Related]
44. Telemedicine-based medical care compared to in-person medical care for warfarin follow-up: A retrospective propensity score matching cohort study.
Alkhuzaee F; Alsharif S; Shukry M
Am J Health Syst Pharm; 2024 Mar; 81(7):e166-e173. PubMed ID: 38070197
[TBL] [Abstract][Full Text] [Related]
45. Implementation of a technician success and onboarding coordinator to reduce technician turnover.
Arrona KL
Am J Health Syst Pharm; 2024 Apr; 81(9):e249-e255. PubMed ID: 38141655
[TBL] [Abstract][Full Text] [Related]
46. Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium.
Snel M; Descamps OS
Acta Cardiol; 2024 May; 79(3):311-318. PubMed ID: 37767917
[No Abstract] [Full Text] [Related]
47. Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study.
Sloot R; Breskin A; Colantonio LD; Allmon AG; Yu Y; Sakhuja S; Chen L; Muntner P; Brookhart MA; Dhalwani N
Epidemiology; 2024 Jul; 35(4):579-588. PubMed ID: 38629975
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of a hybrid protocol using continuous glucose monitoring and point-of-care testing in non-critically ill patients in a community hospital.
Baker M; Lauterwasser S; Valenti C; Kallenberger M; Stolte H
Am J Health Syst Pharm; 2024 Apr; 81(9):e261-e267. PubMed ID: 38146957
[TBL] [Abstract][Full Text] [Related]
49. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
50. Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
Weisshaar S; Zeitlinger M
Drugs; 2018 Jun; 78(8):799-808. PubMed ID: 29737499
[TBL] [Abstract][Full Text] [Related]
51. Recent and anticipated novel drug approvals for 2024.
Rim MH; Karas BL; Barada F; Levitsky AM
Am J Health Syst Pharm; 2024 May; 81(10):385-389. PubMed ID: 38373160
[TBL] [Abstract][Full Text] [Related]
52. Recent and anticipated novel drug approvals for 2023 and 2024.
Rim MH; Karas BL; Barada F; Levitsky AM
Am J Health Syst Pharm; 2024 Mar; 81(6):199-203. PubMed ID: 38146706
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
[TBL] [Abstract][Full Text] [Related]
54. The effect of potassium supplementation and concomitant medications on potassium homeostasis for hospitalized patients.
Montepara CA; Bortmas MR; Cochenour CJ; Fleming MK; Gaffey SH; McQuigg MA; Parisi MK; Zimmerman DE; Covvey JR; Nemecek BD
Am J Health Syst Pharm; 2024 Mar; 81(6):183-189. PubMed ID: 38070196
[TBL] [Abstract][Full Text] [Related]
55. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Navarese EP; Kolodziejczak M; Schulze V; Gurbel PA; Tantry U; Lin Y; Brockmeyer M; Kandzari DE; Kubica JM; D'Agostino RB; Kubica J; Volpe M; Agewall S; Kereiakes DJ; Kelm M
Ann Intern Med; 2015 Jul; 163(1):40-51. PubMed ID: 25915661
[TBL] [Abstract][Full Text] [Related]
56. Considerations and limitations of buprenorphine prescribing for opioid use disorder in the intensive care unit setting: A narrative review.
Erstad BL; Glenn MJ
Am J Health Syst Pharm; 2024 Mar; 81(6):171-182. PubMed ID: 37979138
[TBL] [Abstract][Full Text] [Related]
57. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
Pérez de Isla L; Ray KK; Watts GF; Santos RD; Alonso R; Muñiz-Grijalvo O; Diaz-Diaz JL; Badimon L; Catapano AL; Mata P
Atherosclerosis; 2019 Jul; 286():40-45. PubMed ID: 31100618
[TBL] [Abstract][Full Text] [Related]
58. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
59. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
60. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials.
Bai J; Gong LL; Li QF; Wang ZH
J Clin Lipidol; 2018; 12(2):277-291.e3. PubMed ID: 29428832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
